A single-arm, open-label, phase II study to assess the safety and efficacy of the trifunctional antibody catumaxomab (Anti-EpCAM x Anti-CD3) administered intraperitoneally in ovarian cancer patients with recurrent symptomatic malignant ascites

Trial Profile

A single-arm, open-label, phase II study to assess the safety and efficacy of the trifunctional antibody catumaxomab (Anti-EpCAM x Anti-CD3) administered intraperitoneally in ovarian cancer patients with recurrent symptomatic malignant ascites

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Malignant ascites; Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Neovii Biotech
  • Most Recent Events

    • 11 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Trial design details presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
    • 16 Feb 2010 Planned end date (1 Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top